STAT+: FDA expert panel recommends against approval of Capricor’s Duchenne drug
STAT News · LC · trust 44/100
STAT is live-blogging an FDA meeting on Capricor Therapeutics’ treatment for Duchenne muscular dystrophy, which has been the subject of a contentious regulatory review.
Read the original at STAT News →
Open in TruthVane →